RASolute
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...